Wenjie Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenjie Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Ding Cheng
Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publicationsHaixia Liu
Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications- Hongjun Yang
Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China
2 shared publications - Hongwei Wu
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
2 shared publications - Xinyu Wan
Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications - Bo Zhang
Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang 330115, China
1 shared publication
Latest Publications
- Open Access
- 8 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Psoralen enhances direct cardiac reprogramming via activating PPARα and driving mitochondrial fission and improves cardiac function after myocardial infarction
Direct cardiac reprogramming offers a promising strategy to regenerate cardiomyocytes for heart repair, but its efficiency and maturation remain limited. P
- 8 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessPsoralen enhances direct cardiac reprogramming via activating PPARα and driving mitochondrial fission and improves cardiac function after myocardial infarction
Direct cardiac reprogramming offers a promising strategy to regenerate cardiomyocytes for heart repair, but its efficiency and maturation remain limited. P
- Open Access
- 29 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 704
Active Constituents and Mechanisms of Xinshubao Tablets in Coronary Vasorelaxation
Background: Xinshubao tablet (XSB), a traditional Chinese medicine (TCM) formula composed of five medicinal herbs, is used clinically to alleviate cardiovascular diseases. This study aimed to investigate the coronary vasodilatory effects of XSB and its individual herbs, exploring its active constituents and the underlying mechanisms. Methods: The vasorelaxant effects of XSB and its individual herbal intestinal absorption solutions (IASs) were evaluated by ex vivo coronary artery ring assays. The chemical constituents of the best active herbal IAS were qualitatively identified using ultra-performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UPLC–Q-TOF-MS). Molecular docking and ex vivo assays were used to predict and validate the bioactive constituents and mechanisms responsible for coronary vasorelaxation. Results: Vasodilation experiments revealed that XSB-IAS and its individual herb IAS exhibited varying degrees of vasodilatory effects, in the range of 0.8–18 g raw materials/mL. At 6, 12, and 18 mg of raw materials/mL, Crataegus pinnatifida Bge (Shanzha) exhibited vasodilation rates of 26.45% ± 1.8%, 36.57% ± 3.5%, and 45.16% ± 6.3%, which were obviously higher than those of the other individual herbs. Fifty constituents in Shanzha IAS were identified by UPLC-Q-TOF-MS. Vasodilation-related protein–protein interaction (PPI) network revealed NOS3 as a core regulatory target. Molecular docking demonstrated that among the identified constituents, isochlorogenic acid B, betulin, etc., displayed binding affinity to NOS3. Isochlorogenic acid B was further validated to exhibit vasodilatory effects in the ranges of 0.05–2.5 mM. Mechanistic results showed that isochlorogenic acid B improved vasodilation by inhibiting Ca2+ influx through both voltage-dependent and receptor-operated Ca2+ channels, activating K+ channels, and exhibiting endothelium-dependent vasorelaxation. Conclusions: This study provides insights into the material basis and mechanisms underlying the vasorelaxant effects of XSB. Isochlorogenic acid B was firstly found to exert the coronary vasodilatory effect. This study can also contribute to the identification of efficacy-related quality markers in TCM.
- 29 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 704
Open AccessActive Constituents and Mechanisms of Xinshubao Tablets in Coronary Vasorelaxation
Background: Xinshubao tablet (XSB), a traditional Chinese medicine (TCM) formula composed of five medicinal herbs, is used clinically to alleviate cardiovascular diseases. This study aimed to investigate the coronary vasodilatory effects of XSB and its individual herbs, exploring its active constituents and the underlying mechanisms. Methods: The vasorelaxant effects of XSB and its individual herbal intestinal absorption solutions (IASs) were evaluated by ex vivo coronary artery ring assays. The chemical constituents of the best active herbal IAS were qualitatively identified using ultra-performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UPLC–Q-TOF-MS). Molecular docking and ex vivo assays were used to predict and validate the bioactive constituents and mechanisms responsible for coronary vasorelaxation. Results: Vasodilation experiments revealed that XSB-IAS and its individual herb IAS exhibited varying degrees of vasodilatory effects, in the range of 0.8–18 g raw materials/mL. At 6, 12, and 18 mg of raw materials/mL, Crataegus pinnatifida Bge (Shanzha) exhibited vasodilation rates of 26.45% ± 1.8%, 36.57% ± 3.5%, and 45.16% ± 6.3%, which were obviously higher than those of the other individual herbs. Fifty constituents in Shanzha IAS were identified by UPLC-Q-TOF-MS. Vasodilation-related protein–protein interaction (PPI) network revealed NOS3 as a core regulatory target. Molecular docking demonstrated that among the identified constituents, isochlorogenic acid B, betulin, etc., displayed binding affinity to NOS3. Isochlorogenic acid B was further validated to exhibit vasodilatory effects in the ranges of 0.05–2.5 mM. Mechanistic results showed that isochlorogenic acid B improved vasodilation by inhibiting Ca2+ influx through both voltage-dependent and receptor-operated Ca2+ channels, activating K+ channels, and exhibiting endothelium-dependent vasorelaxation. Conclusions: This study provides insights into the material basis and mechanisms underlying the vasorelaxant effects of XSB. Isochlorogenic acid B was firstly found to exert the coronary vasodilatory effect. This study can also contribute to the identification of efficacy-related quality markers in TCM.
- Open Access
- 23 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 279
Psoralen Promotes Direct Chemical Reprogramming of Mouse Embryonic Fibroblasts into Osteoblast-like Cells
Background/Objectives: Cells derived from direct chemical reprogramming into osteoblasts represent a promising source for bone regeneration, but the efficiency needs improvement. Here, we systematically evaluated whether the natural compound psoralen (Psr) could enhance this process and explored its therapeutic potential and mechanism of action. Methods: Mouse embryonic fibroblasts (MEFs) were treated with a cocktail of forskolin and phenamil (FP), supplemented with Psr. In vitro differentiation was assessed by alkaline phosphatase and Alizarin Red S staining, reverse transcription quantitative PCR, immunofluorescence and Western blot. The bone-regenerative potential of the derived chemically induced osteoblast-like cells (ciOBs) was evaluated in critical-sized calvarial defects, femoral cortical defects and a subcutaneous ectopic implantation model, using micro-computed tomography and histology. Mechanistic insights of Psr were gained by analyzing the adenylyl cyclase 9 (ADCY9)/cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/cAMP response element-binding protein (CREB) axis using inhibitor SQ22536. Results: Psr acted synergistically with the FP cocktail to drive efficient osteogenic reprogramming of MEFs. At an optimal concentration of 25 μM, Psr enabled the most robust induction of early osteogenic markers and generation of mature, mineralizing ciOBs in vitro. In vivo, FP + Psr-induced ciOBs repaired critical-sized calvarial and femoral cortical defects and generated substantial, vascularized bone tissue in ectopic sites. Mechanistically, Psr co-treatment potently activated the ADCY9/cAMP/PKA/CREB pathway, and pharmacological inhibition of this pathway completely abolished the pro-osteogenic effects of Psr. Conclusions: Psr acts as a potent synergistic enhancer of direct chemical reprogramming, generating functional osteoblast-like cells with robust bone-regenerative capacity via activation of the ADCY9/cAMP/PKA/CREB pathway.
- 23 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 279
Open AccessPsoralen Promotes Direct Chemical Reprogramming of Mouse Embryonic Fibroblasts into Osteoblast-like Cells
Background/Objectives: Cells derived from direct chemical reprogramming into osteoblasts represent a promising source for bone regeneration, but the efficiency needs improvement. Here, we systematically evaluated whether the natural compound psoralen (Psr) could enhance this process and explored its therapeutic potential and mechanism of action. Methods: Mouse embryonic fibroblasts (MEFs) were treated with a cocktail of forskolin and phenamil (FP), supplemented with Psr. In vitro differentiation was assessed by alkaline phosphatase and Alizarin Red S staining, reverse transcription quantitative PCR, immunofluorescence and Western blot. The bone-regenerative potential of the derived chemically induced osteoblast-like cells (ciOBs) was evaluated in critical-sized calvarial defects, femoral cortical defects and a subcutaneous ectopic implantation model, using micro-computed tomography and histology. Mechanistic insights of Psr were gained by analyzing the adenylyl cyclase 9 (ADCY9)/cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/cAMP response element-binding protein (CREB) axis using inhibitor SQ22536. Results: Psr acted synergistically with the FP cocktail to drive efficient osteogenic reprogramming of MEFs. At an optimal concentration of 25 μM, Psr enabled the most robust induction of early osteogenic markers and generation of mature, mineralizing ciOBs in vitro. In vivo, FP + Psr-induced ciOBs repaired critical-sized calvarial and femoral cortical defects and generated substantial, vascularized bone tissue in ectopic sites. Mechanistically, Psr co-treatment potently activated the ADCY9/cAMP/PKA/CREB pathway, and pharmacological inhibition of this pathway completely abolished the pro-osteogenic effects of Psr. Conclusions: Psr acts as a potent synergistic enhancer of direct chemical reprogramming, generating functional osteoblast-like cells with robust bone-regenerative capacity via activation of the ADCY9/cAMP/PKA/CREB pathway.
- Open Access
Psoralen Enhances Direct Cardiac Reprogramming via PPARα Activation and Promotion of Mitochondrial Fission
BACKGROUND: Cell-based therapy is a promising strategy for heart repair and regeneration. However, its clinical application has been hampered by the low efficiency of cell direct reprogramming and the immature state of the inducing cells. Developing novel strategies to enhance direct reprogramming efficiency and yield mature functional cardiomyocytes remains a critical challenge. METHODS: We evaluated the effect of Psr on cardiac reprogramming using RepSox and Forskolin (RF) as the baseline cocktail. Reprogramming efficiency, cardiomyocyte marker expression, and calcium handling were assessed by RT-qPCR, immunofluorescence. Ultrastructural features were examined by transmission electron microscopy. Metabolic profiles were analyzed using Seahorse assays. Transcriptomic changes were explored by RNA sequencing, followed by pathway and protein–protein interaction analyses. A myocardial infarction (MI) mouse model was used for in vivo validation. RESULTS: Supplementation with Psr (10 μM) markedly enhanced the induction of induced cardiomyocytes (iCMs), leading to earlier appearance of beating clusters (day 1 vs. day 6–8), improved sarcomere organization, robust calcium transients, and higher energy metabolism. Transcriptomic profiling identified activation of the PPAR signaling pathway, with PPARα, RXRG, and UCP1 as central regulators. Mechanistically, Psr promoted mitochondrial fission, thereby facilitating metabolic remodeling essential for cardiomyocyte maturation. In vivo, RF+Psr treatment significantly improved cardiac function and reduced fibrosis after MI compared to RF alone. CONCLUSION: Psr enhances direct cardiac reprogramming by activating PPAR signaling and promoting mitochondrial fission. These findings provide a novel mechanistic framework and suggest psoralen as a promising natural enhancer for cardiac regeneration strategies. Graphical
Open AccessPsoralen Enhances Direct Cardiac Reprogramming via PPARα Activation and Promotion of Mitochondrial Fission
BACKGROUND: Cell-based therapy is a promising strategy for heart repair and regeneration. However, its clinical application has been hampered by the low efficiency of cell direct reprogramming and the immature state of the inducing cells. Developing novel strategies to enhance direct reprogramming efficiency and yield mature functional cardiomyocytes remains a critical challenge. METHODS: We evaluated the effect of Psr on cardiac reprogramming using RepSox and Forskolin (RF) as the baseline cocktail. Reprogramming efficiency, cardiomyocyte marker expression, and calcium handling were assessed by RT-qPCR, immunofluorescence. Ultrastructural features were examined by transmission electron microscopy. Metabolic profiles were analyzed using Seahorse assays. Transcriptomic changes were explored by RNA sequencing, followed by pathway and protein–protein interaction analyses. A myocardial infarction (MI) mouse model was used for in vivo validation. RESULTS: Supplementation with Psr (10 μM) markedly enhanced the induction of induced cardiomyocytes (iCMs), leading to earlier appearance of beating clusters (day 1 vs. day 6–8), improved sarcomere organization, robust calcium transients, and higher energy metabolism. Transcriptomic profiling identified activation of the PPAR signaling pathway, with PPARα, RXRG, and UCP1 as central regulators. Mechanistically, Psr promoted mitochondrial fission, thereby facilitating metabolic remodeling essential for cardiomyocyte maturation. In vivo, RF+Psr treatment significantly improved cardiac function and reduced fibrosis after MI compared to RF alone. CONCLUSION: Psr enhances direct cardiac reprogramming by activating PPAR signaling and promoting mitochondrial fission. These findings provide a novel mechanistic framework and suggest psoralen as a promising natural enhancer for cardiac regeneration strategies. Graphical
- Open Access
- 19 July 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (14) , e70712
Daqinjiao Decoction Ameliorates CSVD via RXR‐γ/PPAR‐γ/VEGF‐α Pathway: Insights From Transcriptome Sequencing and Network Pharmacology
Daqinjiao decoction (DQJD), an ancient traditional Chinese medicine formula, is clinically used in the treatment of cerebral small vessel disease (CSVD). However, the underlying molecular mechanisms by which DQJD exerts its therapeutic effects on CSVD remain elusive. A Sprague Dawley rat model of chronic cerebral hypoperfusion (CCH) was established using bilateral common carotid artery occlusion (BCCAO) surgery. The effects of DQJD administered via intragastric gavage (i.g.) were evaluated by magnetic resonance imaging (MRI), haematoxylin eosin (HE) staining, and transmission electron microscopy. A combined strategy of transcriptomics and network pharmacology was innovatively applied to study the active ingredients, gene targets, and mechanisms of DQJD in treating CSVD. Molecular docking, real‐time quantitative polymerase chain reaction (RT‐qPCR), and Western blot analysis were applied to confirm the above results further. DQJD improved the pathological damage in cortical and hippocampal tissue by reducing the release of inflammatory factors in CCH rats. RNA‐seq technology identified 46 DEGs between DQJD treatment and the model group. Network pharmacology and pathway analysis of DEGs revealed that the PPAR/VEGF signalling pathway was predicted to be significantly affected. Consistently, validation experiments confirmed that activation of the RXR‐γ/PPAR‐γ/VEGF‐α signalling pathway represents a key mechanism underlying DQJD's therapeutic effects against CSVD. DQJD dampened inflammation and ameliorated pathological damage in the hippocampus and cortex, and these beneficial effects were associated with neurovascular protection via activating the RXR‐γ/PPAR‐γ/VEGF‐α pathway.
- 19 July 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (14) , e70712
Open AccessDaqinjiao Decoction Ameliorates CSVD via RXR‐γ/PPAR‐γ/VEGF‐α Pathway: Insights From Transcriptome Sequencing and Network Pharmacology
Daqinjiao decoction (DQJD), an ancient traditional Chinese medicine formula, is clinically used in the treatment of cerebral small vessel disease (CSVD). However, the underlying molecular mechanisms by which DQJD exerts its therapeutic effects on CSVD remain elusive. A Sprague Dawley rat model of chronic cerebral hypoperfusion (CCH) was established using bilateral common carotid artery occlusion (BCCAO) surgery. The effects of DQJD administered via intragastric gavage (i.g.) were evaluated by magnetic resonance imaging (MRI), haematoxylin eosin (HE) staining, and transmission electron microscopy. A combined strategy of transcriptomics and network pharmacology was innovatively applied to study the active ingredients, gene targets, and mechanisms of DQJD in treating CSVD. Molecular docking, real‐time quantitative polymerase chain reaction (RT‐qPCR), and Western blot analysis were applied to confirm the above results further. DQJD improved the pathological damage in cortical and hippocampal tissue by reducing the release of inflammatory factors in CCH rats. RNA‐seq technology identified 46 DEGs between DQJD treatment and the model group. Network pharmacology and pathway analysis of DEGs revealed that the PPAR/VEGF signalling pathway was predicted to be significantly affected. Consistently, validation experiments confirmed that activation of the RXR‐γ/PPAR‐γ/VEGF‐α signalling pathway represents a key mechanism underlying DQJD's therapeutic effects against CSVD. DQJD dampened inflammation and ameliorated pathological damage in the hippocampus and cortex, and these beneficial effects were associated with neurovascular protection via activating the RXR‐γ/PPAR‐γ/VEGF‐α pathway.
- 27 September 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319 (Pt 2) , 117236
Quality evaluation of Angelica Sinensis Radix dispensing granules by integrating microvascular activity and chemical analysis
- 27 September 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319 (Pt 2) , 117236
Quality evaluation of Angelica Sinensis Radix dispensing granules by integrating microvascular activity and chemical analysis